Blu – Pagina 156 – AMD

Blu

Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.

Luglio 11, 2023 dario.olivero

A comparison of faster insulin aspart to standard insulin aspart using hybrid automated insulin delivery system in active children and adolescents with type 1 diabetes: a randomized, double-blind crossover trial

Dovc K, Bergford S, Fröhlich-Reiterer E, et al.
Diabetes Technol Ther. Pub. online 5 Jul 2023.

Leggi

Luglio 11, 2023 dario.olivero

Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study

Fan M, Stephan AJ, Emmert-Fees K, et al.
Diabetologia. Pub. online 30 Jun 2023.

Leggi

Luglio 7, 2023 dario.olivero

The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials

Bjorner JB, Larsen S, Lübker C, Holst-Hansen T
Diabetes Obes Metab. 2023;25(8):2142-2150.

Leggi

Luglio 7, 2023 dario.olivero

Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial

Zhang L, Zhang Y, Shen S, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00132-8.

Leggi

Luglio 7, 2023 dario.olivero

Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial

Svanevik M, Lorentzen J, Borgeraas H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00127-4.

Leggi

Luglio 7, 2023 dario.olivero

Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study

Larose S, Filliter C, Platt RW, et al.
Diabetes Obes Metab. 2023;25(8):2279-2289.

Leggi

Luglio 7, 2023 dario.olivero

Effect of multifactorial intensive treatment in patients with diabetic kidney disease: A meta‐analysis with trial sequential analysis

Shan J, Xu Z
Diabetes Obes Metab. 2023;25(8):2163-2170.

Leggi

Luglio 7, 2023 dario.olivero

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

Kang A, Smyth B, Neuen BL, et al.
Diabetes Obes Metab. 2023;25(8):2151-2162.

Leggi

Giugno 30, 2023 dario.olivero

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.

Aroda VR, Aberle J, Bardtrum L, et al.
The Lancet 2023. Pub. online 25 June 2023.

Leggi

Giugno 30, 2023 dario.olivero

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Frias JP, Deenadayalan S, Erichsen L, et al.
The Lancet 2023. Pub. online 23 June 2023.

Leggi